Search

Your search keyword '"Rebecca, Vito W."' showing total 308 results

Search Constraints

Start Over You searched for: Author "Rebecca, Vito W." Remove constraint Author: "Rebecca, Vito W."
308 results on '"Rebecca, Vito W."'

Search Results

3. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma

5. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer

6. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.

7. Stromal changes in the aged lung induce an emergence from melanoma dormancy

8. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma

9. Persister state-directed transitioning and vulnerability in melanoma

10. Targeting the cyclin-dependent kinase 5 in metastatic melanoma

12. Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors

13. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma

24. Diversity, equity, and inclusion in the melanoma research community

25. Supplementary Data from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

26. Supplementary Movie 1 from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

27. Supplementary Movie 2 from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

28. Data from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

30. Supplementary Video 7 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

31. Data from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

33. Supplementary Figures from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

35. Supplementary Video 2 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

36. Supplementary Movie 2 (SM2) from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

37. Supplementary Video 6 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

38. Supplementary Figures from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

39. Supplementary Video 5 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

40. Supplemental Figures S1-S7 and Supplemental Table S1 from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

41. Supplementary Figures S1-S4 from PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer

42. Data from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

43. Supplementary Movie 1 (SM1) from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

44. Supplementary Video 4 from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

45. Chemical Methods from A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles

46. Data from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

47. Supplementary Movie 1 from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

48. Supplementary Tables from Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling

49. Supplementary Movie 2 from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

50. Chemical Methods from PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer

Catalog

Books, media, physical & digital resources